Abstract

Serogroup B meningococcal disease (MenB) causes almost 60% of meningitis cases among adolescents and young adults. Yet, MenB vaccine coverage among adolescents remains below 10%. Since parents are the primary medical decision makers for adolescents, we examined MenB vaccination rates and parent attitudes about meningitis and the MenB vaccine. In 2018, in conjunction with a county-wide, school-based immunization campaign, we conducted a mixed methods study among parents of 16- to 17-year-olds. We facilitated focus groups asking parents about their knowledge of meningitis and reactions to educational materials and sent behavioral surveys based on Health Belief Model constructs to parents through the county high school system. Parents in three focus groups (n = 8; participation rate = 13%) expressed confusion about their child’s need to receive the MenB vaccine in addition to the meningococcal conjugate vaccine (MenACWY), but conveyed strong trust in their physicians’ recommendation. Among survey participants (n = 170), 70 (41%) had heard of the MenB vaccine. Among those 70 parents, the most common barriers to vaccination were concerns about side effects (55%) and uncertainty of susceptibility due to receipt of the MenACWY vaccine (30%). The percentage of teens that received at least one dose of the MenB vaccine was 50% (n = 35) by parent report and 23% (n = 16) by state vaccination records. Parents demonstrated uncertainty and confusion about the MenB vaccine particularly due to the existence of another meningitis vaccine and limited health care provider recommendations. Confirmatory studies of parent confusion about the MenB vaccine are needed to develop interventions.

Highlights

  • Between 2014 and 2016, serogroup B (MenB) was the cause of 58% of the 166 cases of meningococcal disease in persons aged 18 to 24 years in the United States [1, 2]

  • Similar to other new vaccines, only half of the parents had heard of the meningococcal B (MenB) vaccine and the majority of those who heard about it were concerned about side effects [34]

  • A similar phenomena may be occurring for MenB vaccine

Read more

Summary

Introduction

Between 2014 and 2016, serogroup B (MenB) was the cause of 58% of the 166 cases of meningococcal disease in persons aged 18 to 24 years in the United States [1, 2]. Within the United States, to our knowledge, only two studies examined parents’ awareness about and intention for their highschool-aged children to receive the MenB vaccine [13, 14]. In this study, compared to parents who had not heard of the vaccine, the odds of parents’ intent to have their child vaccinated increased nearly fourfold among parents aware of the MenB vaccine and threefold among parents at least somewhat concerned about meningitis. Understanding more about parent attitudes could help develop and adapt interventions to increase MenB vaccination and reduce MenB meningitis cases

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call